Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07825753). This is a study registration, not published results. Lead sponsor: Fudan University. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 225 participants (ESTIMATED). Conditions: Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC). Interventions: DRUG: Trastuzumab emtansine (T-DM1); DRUG: Trastuzumab deruxtecan (T-DXd); DRUG: Datopotamab deruxtecan (Dato-DXd); DRUG: Sacituzumab govitecan (SG); DRUG: Enfortumab vedotin (EV); DRUG: Becotatug vedotin (MRG003); DRUG: Izalontamab brengitecan (iza-bren / BL-B01D1); DRUG: Mirvetuximab soravtansine (MIRV). Primary outcome measures: Objective Response Rate (ORR) as Assessed by RECIST 1.1 , Up to 104 Weeks. Brief summary: To evaluate the clinical efficacy (objective response rate, ORR) of mass spectrometry-based absolute quantification-guided selection and matching of ADC/PDC therapy in patients with locally advanced or metastatic pancreatic cancer/breast cancer, and to explore a quantitative threshold-based stratification strategy for identifying a "hidden benefit population